Physician profile
Mary E Buck
NPI 1871665208
$3,157.63
in general payments reported to CMS, 2019-2025
17 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $872 · 2023: $810 · 2024: $477 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,615.67 | 2021-2025 | |
| Janssen Biotech, INC. | $436.19 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.00 | 2021-2023 | Xifaxan, Trulance |
| Qol Medical, LLC | $232.86 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $152.17 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $99.94 | 2021-2023 | Talicia |
| Merck Sharp & Dohme LLC | $62.10 | 2021-2022 | |
| Gilead Sciences, INC. | $54.78 | 2025 | |
| Nestle Healthcare Nutrition INC. | $50.35 | 2022 | |
| Boston Scientific Corporation | $44.60 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $44.31 | 2022-2025 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $19.12 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.42 | 2022 | |
| Amgen INC. | $17.85 | 2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $16.62 | 2024 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $13.77 | 2022 | |
| Intercept Pharmaceuticals, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.